RxDoctor Payments Data

Phillip Horne, MD

Orthopaedic Surgery of the Spine · Cary, NCNPI 1073757720

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (35.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Globus Medical accounts for 79.9% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2021 at $17,810 and has fallen 69.5% since, to $5,424 in 2025.

$45,100in general payments, 2019–2025

Across 115 payments — averaging $392.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Globus Medical$36K
  • Restor3d, Inc.$6K
  • Abbott$1K
  • Boston Scientific$1K
  • Medtronic$513
  • Cerapedics Inc.$261
  • plus $107 from 4 others
$159,340in research payments, 2019–2025

Across 6 payments — averaging $26,557 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Globus Medical$159K
$180,538in ownership & investment interests, 2019–2025

Across 1 payment — averaging $180,538 each. An ownership or investment interest held by the physician or an immediate family member.

  • Restor3d, Inc.$181K

What the payments were for

  • Royalty or licence$5,66613%
  • Consulting fees$16,10036%
  • Speaking & faculty fees$10,01322%
  • Travel & lodging$9,67121%
  • Food & beverage$3,3898%
  • Education$2611%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$45,100 in reported general payments places this provider in the 75th percentile of 32 orthopaedic surgery of the spine providers in North Carolina.

See all orthopaedic surgery of the spine providers in North Carolina

Medicare billing

Part B allowed, 2024
$182,442
Medicare patients
139
Services billed
789

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gabapentin78$746
Oxycodone Hcl87$701
Pregabalin36$618
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen65$494
Methylprednisolone56$346
Tizanidine Hcl38$275
Methocarbamol25$244
Diclofenac Sodium16$174
Meloxicam58$155
Celecoxib12$155
Diazepam37$54
Tramadol Hcl14$40

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery of the spine in Cary

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →